抄録
While bisphosphonates have been shown to decrease the risk of vertebral and femoral neck fractures in osteoporotic patients, recent reports have associated long-term use of bisphosphonate with low-energy diaphyseal femoral fracture.
This article describes a 68-year-old woman who presented with low-energy right femur fracture. She had been taking alendronate for treatment of steroid osteoporosis for 5 years and had a contralateral diaphyseal stress fracture at the time of the initial fracture. The stress fracture did not heal, and 1 year and 3 months later, she suffered sequential contralateral femoral fracture.
Several reports have recommended temporary or permanent discontinuation of bisphosphonate in such patients. However, the benefit of bisphosphonate for treatment of osteoporosis cannot be neglected.
As there is little likelihood that stress fracture can be cured, we recommend that prophylactic fixation should be considered if such a fracture is found in the contralateral limb.
